Literature DB >> 35969333

Discovery of newer pyrazole derivatives with potential anti-tubercular activity via 3D-QSAR based pharmacophore modelling, virtual screening, molecular docking and molecular dynamics simulation studies.

Palmi Modi1,2, Shivani Patel1,3, Mahesh Chhabria4.   

Abstract

Tuberculosis is one of the leading causes of death of at least one million people annually. The deadliest infectious disease has caused more than 120 million deaths in humans since 1882. The cell wall structure of Mycobacterium tuberculosis is important for survival in the host environment. InhA is the foremost target for the development of novel anti-tubercular agents. Therefore, we report pharmacophore-based virtual screening (ZINC and ASINEX databases) and molecular docking study (PDB Code: 4TZK) to identify and design potent inhibitors targeting to InhA. A five-point pharmacophore model AADHR_1 (with R2 = 0.97 and Q2 = 0.77) was developed by using 47 compounds with its reported MIC values. Further, to identify and design potent hit molecules based on lead identification and modification, generated hypothesis employed for virtual screening using ZINC and ASINEX databases. Predicted pyrazole derivatives further gauged for drug likeliness and docked against enoyl acyl carrier protein reductase to categorize the essential amino acid interactions to the active site of the enzyme. Structure elucidation of these synthesized compounds was carried out using IR, MS, 1H-NMR and 13C-NMR spectroscopy. Amongst all the synthesized compounds, some of the compounds 5a, 5c, 5d and 5e were found to be potent with their MIC ranging from 2.23 to 4.61 µM. Based on preliminary anti-tubercular activity synthesized potent molecules were further assessed for MDR-TB, XDR-TB and cytotoxic study.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  3D-QSAR; Anti-tubercular activity; Molecular docking; Pharmacophore modelling; Pyrazole; Virtual screening

Year:  2022        PMID: 35969333     DOI: 10.1007/s11030-022-10511-8

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   3.364


  31 in total

1.  World TB Day 2017: Advances, Challenges and Opportunities in the "End-TB" Era.

Authors:  Eskild Petersen; Markus Maeurer; Ben Marais; Giovanni Battista Migliori; Peter Mwaba; Francine Ntoumi; Cris Vilaplana; Kami Kim; Marco Schito; Alimuddin Zumla
Journal:  Int J Infect Dis       Date:  2017-02-21       Impact factor: 3.623

Review 2.  Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis.

Authors:  Kuni Takayama; Cindy Wang; Gurdyal S Besra
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Hydrogen peroxide-mediated isoniazid activation catalyzed by Mycobacterium tuberculosis catalase-peroxidase (KatG) and its S315T mutant.

Authors:  Xiangbo Zhao; Hong Yu; Shengwei Yu; Feng Wang; James C Sacchettini; Richard S Magliozzo
Journal:  Biochemistry       Date:  2006-04-04       Impact factor: 3.162

4.  Novel 2-(2-phenalkyl)-1H-benzo[d]imidazoles as antitubercular agents. Synthesis, biological evaluation and structure-activity relationship.

Authors:  Katarzyna Gobis; Henryk Foks; Karolina Suchan; Ewa Augustynowicz-Kopeć; Agnieszka Napiórkowska; Krzysztof Bojanowski
Journal:  Bioorg Med Chem       Date:  2015-03-09       Impact factor: 3.641

Review 5.  Comprehensive Review in Current Developments of Benzimidazole-Based Medicinal Chemistry.

Authors:  Rangappa S Keri; Asha Hiremathad; Srinivasa Budagumpi; Bhari Mallanna Nagaraja
Journal:  Chem Biol Drug Des       Date:  2014-11-28       Impact factor: 2.817

6.  The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.

Authors:  R Baur; J Gertsch; E Sigel
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

7.  [Action of the anti-inflammatory agent Lonazolac on experimentally-induced acute inflammation of human skin].

Authors:  J Dethlefs
Journal:  Z Rheumatol       Date:  1978 Jul-Aug       Impact factor: 1.372

Review 8.  Benzimidazole-core as an antimycobacterial agent.

Authors:  Rangappa S Keri; Chethana Kolambae Rajappa; Siddappa A Patil; Bhari Mallanna Nagaraja
Journal:  Pharmacol Rep       Date:  2016-08-04       Impact factor: 3.024

9.  The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.

Authors:  Y Zhang; B Heym; B Allen; D Young; S Cole
Journal:  Nature       Date:  1992-08-13       Impact factor: 49.962

10.  3D QSAR-based design and liquid phase combinatorial synthesis of 1,2-disubstituted benzimidazole-5-carboxylic acid and 3-substituted-5H-benzimidazo[1,2-d][1,4]benzodiazepin-6(7H)-one derivatives as anti-mycobacterial agents.

Authors:  Nikum D Sitwala; Vivek K Vyas; Piyush Gedia; Kinjal Patel; Rania Bouzeyen; Saqib Kidwai; Ramandeep Singh; Manjunath D Ghate
Journal:  Medchemcomm       Date:  2019-03-22       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.